In combination with emerging clinical and experimental evidence, we also discuss several important and long-term unanswered questions regarding stromal AR niches in promoting prostate epithelial oncogenesis, and tumor development and progression, and highlight future therapeutic strategies for co-targeting both epithelial and stromal AR oncogenic effects for treating advanced PCa. This evidence concerns the gene AR and neoplasm.